Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical is viewed positively because LIBERTY directly attacks the main adoption barriers in endovascular robotics: it is fully disposable, compact, and priced per procedure, avoiding the $1-$2 million capital burden, service infrastructure, and workflow disruption that often slow hospital purchasing. Its clinical profile is also compelling, with ACCESS-PVI showing a 100% navigation success rate, zero device-related adverse events, a 92% relative reduction in physician radiation exposure, and a median navigation time of about 3 minutes, which strengthens both physician advocacy and institutional demand. With nearly $68 million in cash and no debt, a concentrated initial market of about 2.5 million peripheral endovascular procedures annually, and early commercial traction already emerging, the company appears well funded to scale a recurring-revenue model.

Microbot Medical is a development-stage medical device company with no prior revenue history, and its early sales depend almost entirely on LIBERTY’s commercial acceptance after the April 2026 market release. The bull case is constrained by slow hospital adoption, lack of a dedicated CMS reimbursement code, reliance on existing procedure economics, and execution risks tied to physician training, salesforce deployment, and customer support. Fundamentally, the outlook remains negative because operating expenses are projected to rise from about $15 million in FY25 to $22.5 million in FY26 and $37 million in FY28, while net losses are expected to deepen to roughly $(22) million, $(24) million, and $(26) million in FY26-FY28 despite the company’s 24- to 36-month runway.